Nutex Health price target raised to $60 from $45 at Benchmark

Benchmark analyst Bill Sutherland raised the firm’s price target on Nutex Health (NUTX) to $60 from $45 and keeps a Buy rating on the shares after what the firm calls “another big beat from top to bottom,” with revenue and AEBITDA growth of 26% and 974%, respectively. Initiatives to increase patient volumes with a focus on higher value services point to continued growth and margin expansion, the analyst tells investors.